select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Lennox-Gastaut Syndrome-Pipeline Review, H2 2016

Lennox-Gastaut Syndrome-Pipeline Review, H2 2016


  • Products Id :- GMDHC8798IDB
  • |
  • Pages: 68
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Lennox-Gastaut Syndrome-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lennox-Gastaut Syndrome-Pipeline Review, H2 2016, provides an overview of the Lennox-Gastaut Syndrome (Central Nervous System) pipeline landscape.

Lennox-Gastaut syndrome is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. The most common types of seizures associated with Lennox-Gastaut syndrome are tonic and atonic seizures. Causes of Lennox-Gastaut syndrome include cortical dysplasia, congenital infections, stroke, trauma, perinatal hypoxia, infections of the central nervous system such as encephalitis or meningitis and a rare, genetic disorder called tuberous sclerosis. Treatment includes antiepileptic drugs, dietary therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lennox-Gastaut Syndrome-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Lennox-Gastaut Syndrome.

Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Lennox-Gastaut Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Lennox-Gastaut Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Lennox-Gastaut Syndrome Overview 6

Therapeutics Development 7

Pipeline Products for Lennox-Gastaut Syndrome-Overview 7

Pipeline Products for Lennox-Gastaut Syndrome-Comparative Analysis 8

Lennox-Gastaut Syndrome-Therapeutics under Development by Companies 9

Lennox-Gastaut Syndrome-Therapeutics under Investigation by Universities/Institutes 10

Lennox-Gastaut Syndrome-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Lennox-Gastaut Syndrome-Products under Development by Companies 14

Lennox-Gastaut Syndrome-Products under Investigation by Universities/Institutes 15

Lennox-Gastaut Syndrome-Companies Involved in Therapeutics Development 16

Eisai Co Ltd 16

GW Pharmaceuticals Plc 17

INSYS Therapeutics Inc 18

Zogenix Inc 19

Lennox-Gastaut Syndrome-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 26

Drug Profiles 28

cannabidiol-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

cannabidiol-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

fenfluramine hydrochloride-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

NRP-2945-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

perampanel-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Lennox-Gastaut Syndrome-Product Development Milestones 51

Featured News & Press Releases 51

Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 51

Oct 28, 2016: Eisai To Initiate Two Phase III Clinical Studies For Antiepileptic Drug Perampanel (Fycompa) in Pediatric Patients With Partial-Onset or Primary Generalized Tonic-Clonic Seizures And In Patients With Seizures Associated With Lennox-Gastaut Syndrome 52

Sep 26, 2016: GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 54

Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 56

Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 58

Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 58

Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome 61

May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome 62

Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients 63

Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug 63

Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome 64

May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome 64

Feb 28, 2014: GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex in the Treatment of Lennox-Gastaut Syndrome 65

Sep 25, 2006: FDA Approves New Epilepsy Indication For Lamictal 66

Jan 15, 2004: New Expanded Indication For Lamictal Offers Additional Treatment Options For Adults With Partial Seizures 66

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Figures

Number of Products under Development for Lennox-Gastaut Syndrome, H2 2016 7

Number of Products under Development for Lennox-Gastaut Syndrome-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

List of Tables

Number of Products under Development for Lennox-Gastaut Syndrome, H2 2016 7

Number of Products under Development for Lennox-Gastaut Syndrome-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Lennox-Gastaut Syndrome-Pipeline by Eisai Co Ltd, H2 2016 16

Lennox-Gastaut Syndrome-Pipeline by GW Pharmaceuticals Plc, H2 2016 17

Lennox-Gastaut Syndrome-Pipeline by INSYS Therapeutics Inc, H2 2016 18

Lennox-Gastaut Syndrome-Pipeline by Zogenix Inc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Eisai Co Ltd, GW Pharmaceuticals Plc, INSYS Therapeutics Inc, Zogenix Inc

Lennox-Gastaut Syndrome Therapeutic Products under Development, Key Players in Lennox-Gastaut Syndrome Therapeutics, Lennox-Gastaut Syndrome Pipeline Overview, Lennox-Gastaut Syndrome Pipeline, Lennox-Gastaut Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com